FTH compared with TSHA: revenue, margins and what each company keeps, and the suppliers and customers both name

FTHFaeth Therapeutics, Inc.

Mkt capRevenueRevenue

TSHATaysha Gene Therapies, Inc.

Mkt capRevenueRevenue

Compare

FTHFaeth Therapeutics, Inc.

TSHATaysha Gene Therapies, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FTH1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−6.73%—

TSHA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.4%▼−4.12%×0.31

May 6 '26±14.4%▲+0.58%×0.04

= impliedFTH realized, solidTSHA realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.0%

▲+2.47%

×0.21

Q3 FY25±22.5%▼−4.26%×0.19

FTHFaeth Therapeutics, Inc.

19.33▲+3.45%

Mkt cap$483.0MRevenue—Revenue—

TSHATaysha Gene Therapies, Inc.

4.14▲+0.18%

Regular sessionSep 2 '83

Mkt cap$1.3BRevenue$5MQ4 FY25Revenue$8MFY24

Compare

Regular sessionSep 2 '83

FTHFaeth Therapeutics, Inc.

TSHATaysha Gene Therapies, Inc.

19.33▲+3.45%

Price

4.14▲+0.18%

$483.0M

Mkt cap

$1.3B

—

Revenue

$5MQ4 FY25

—

Revenue

$8MFY24

FTH19.33▲+3.45%vsTSHA4.14▲+0.18%Regular sessionSep 2 '83